openPR Logo
Press release

Subcutaneous Drug Delivery Market & Pipeline Insight

06-30-2017 08:28 AM CET | Health & Medicine

Press release from: PNS Pharma

Subcutaneous sites along with intramuscular and intravenous sites are part of parenteral route of drug entry. Maximum pharmacological benefits of a drug could be achieved by deciding effective route of administration depending upon pharmacodynamic properties of the drug to be used. Subcutaneous route is commonly used for the administration of therapeutics into the body for better drug delivery of lipophilic, proteinecious, small molecule drugs. It is characterized by less vasculature, fat rich and less metabolic activity prevents the degradation of drugs resulting in long last effect and higher therapeutic effects.

Subcutaneous sites are versatile routes of administration that can be used for long-term therapeutic benefits. Implants are also placed in this site due to less nerve ending so that pain or discomfort is not produced when such devices are placed at the site. Owing to enormous fat reserves, they are found to have good absorbability for lipid soluble drugs which allows the researchers to design drugs according to the nature of subcutaneous site. Some drugs can’t be used via other routes due to difference in their biochemical nature could be administrated subcutaneously. This site is metabolically less active due to which administrated drugs have lesser chances of degradation, enzyme activity and metabolic breakdown as a result of which many drugs could be administrated subcutaneously.

Download Report:

http://www.pnspharma.com/buy-report.php?reporttitle=Subcutaneous-Drug-Delivery-Market-%26-Pipeline-Insight

Proteins are important component of several drugs which can’t be administrated through other routes like oral, intravenous or intramuscular. Protein based drugs are sensitive towards pH, extreme acidity, alkalinity and limited bioavailability causing limited number of sites for administration. For instance, insulin hormone for the treatment of Diabetes Miletus is a small protein administrated through subcutaneous route. Orally it can’t be given due to low pH of stomach which will destroy insulin; intramuscularly it will be absorbed to quickly, while intravenous administration may have potentially high life threatening effects. Also, every year large number of protein based drugs are introduced in market for the treatment of various ailments. Subcutaneous sites are found throughout the body consisting of loose interstitial tissues that may be found in upper arm, anterior thigh surface and lower abdominal portion. These places have been found to be safe and effective for the subcutaneous drug administration.

Numerous benefits provided by innovative subcutaneous drugs and delivery devices have caused increase in their demand across the globe. Higher potency, sustained release and uniform absorption drugs from subcutaneous site has allowed patients to get more therapeutic benefits. More physicians prescribe subcutaneous drugs due to minimized side effects and new formulations are some major factors behind increased market penetration. On the other hand, subcutaneous drug delivery devices have made tremendous increase in technological aspects which is expected to gain more shares in coming years. As a result, it is expected that new innovative products with higher therapeutic capabilities will enter in market in coming years.

“Subcutaneous Drug Delivery Market & Pipeline Insight” Report Findings

* Subcutaneous Drug Delivery Market Overview
* Devices for Subcutaneous Drug Delivery
* Subcutaneous Drug Delivery Market Future Prospects
* Subcutaneous Drug Clinical Pipeline by Company, Indication & Phase
* Subcutaneous Drug Clinical Pipeline: 741 Drugs
* Marketed Subcutaneous Drugs: 228 Drugs
* Marketed Subcutaneous Drug Clinical Insight

For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com

Recent Publication

* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Subcutaneous Drug Delivery Market & Pipeline Insight here

News-ID: 603049 • Views:

More Releases from PNS Pharma

Global Gene Therapy Market Opportunity By Clinical Trials Pipeline sales Kymriah …
"Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlight: o Global Gene Therapy Market Opportunity: > US$ 8 Billion o Global Gene Therapy Clinical Pipeline: > 1000 Therapies In Clinical Trials o Commercially Available Gene Therapies: 11 o USA Dominates Global Gene Therapy Pipeline: > 500 Therapies In Clinical Trials o Cancer Accounts For 50% of Global Gene Therapy Trials Download Report: https://www.pnspharma.com/buy-report.php?reporttitle=Global-Gene-Therapy-Market-Opportunity-%26-Clinical-Trials-Insight-2026 Over the years, gene therapy has been highly responsible for decreasing the mortality rate
Global Orphan Drug Market Clinical Trials Pipeline Report Market Study 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria
Global Rare Disease Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria
Global Orphan Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria

All 5 Releases


More Releases for Subcutaneous

Growth Opportunities in the Global Subcutaneous Biologics Market
Increase in Awareness and the number of Diagnosed cases will Drive Demand in Developing Regions In terms of geography, the global market for subcutaneous biologics is segmented into four major regions, namely, North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW). There is huge healthcare spending in countries such as United States and Canada, and high prevalence of diseases such as rheumatoid arthritis and breast cancer. The Centers for
Subcutaneous Injector Sales Market Report 2017
Subcutaneous Injector market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Browse the full report with a table of contents : https://www.reportsandmarkets.com/reports/global-subcutaneous-injector-sales-market-report-2017-1701051 Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Subcutaneous Injector for
Unmet Need Remains for Subcutaneous Sustained Release Injectables
(Amherst, NH) - As patients live longer and the prevalence and incidence of chronic ailments increase across the general population, drug developers and their delivery device partners are adapting to address what will become a significant market opportunity. Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration and reduced dosing frequency. With the shift away from caregiver interaction, drug safety and compliance/adherence
Global Subcutaneous Immunoglobulin Market | MarketResearchReports.biz
Latest industry research report on: Global Subcutaneous Immunoglobulin Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Global Subcutaneous Immunoglobulin Market: Overview Primary humoral immunodeficiency or primary immune deficiency diseases (PIDD) is a group of disorders in which the immune system of an individual does not function properly. In PIDD patients, the number of antibodies produced in the body is not sufficient, or the ones produced are
Subcutaneous Immunoglobulin Market Demand and Growth Upto 2024
Immunoglobulin, commonly known as an antibody, is a Y-shaped protein manufactured primarily by plasma cells. Immunoglobulin is utilized by the immune system to counterbalance pathogens. Subcutaneous injections are administered as vaccines and medications including insulin and immunoglobulin. The process of administering immunoglobulin is known as immunoglobulin therapy. When immunoglobulin therapy is applied below the dermis and epidermis, or cutis, it is known as subcutaneous immunoglobulin. Subcutaneous therapy is useful as
Subcutaneous Immunoglobulin (SCIg) Market: Technologies, Markets and Players
Immunoglobulin, commonly known as an antibody, is a Y-shaped protein manufactured primarily by plasma cells. Immunoglobulin is utilized by the immune system to counterbalance pathogens. Subcutaneous injections are administered as vaccines and medications including insulin and immunoglobulin. The process of administering immunoglobulin is known as immunoglobulin therapy. When immunoglobulin therapy is applied below the dermis and epidermis, or cutis, it is known as subcutaneous immunoglobulin. Subcutaneous therapy is useful as